Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial

Conclusion
EMB does not reduce the number of anti-vascular endothelial growth factor (VEGF) injections, either within or outside of a trial setting, and is associated with worse BCVA than anti-VEGF monotherapy.

Trial registration number
NCT01006538.

Source: British Journal of Ophthalmology - June 22, 2023 Category: Opthalmology Authors: Jackson, T. L., Soare, C., Petrarca, C., Simpson, A., Neffendorf, J. E., Petrarca, R., Muldrew, K. A., Peto, T., Chakravarthy, U., Membrey, L., Haynes, R., Costen, M., Steel, D. H. W., Desai, R., for the MERLOT Study Group, Bishop, Doyle, Elghrably, Gupta Tags: Editor's choice Original articles - Clinical science Source Type: research